News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

July 24, 2023 Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
July 10, 2023 Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 7, 2023 Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 25, 2023 Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
May 5, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2023 Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
May 3, 2023 Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
April 27, 2023 Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results